Reports from University Medical Center, Department of Surgery highlight recent research in carcinoma therapy
2009 AUG 3 - (NewsRx.com) -- Fresh data on carcinoma are presented in the report 'Safety of gastric resections during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis.' According to a study from Regensburg, Germany, "Cytoreductive surgery (CRS) including gastric resection combined with hyperthermic intraperitoneal chemotherapy (HIPEC) can improve the prognosis of selected patients with peritoneal surface malignancies. Perioperative morbidity of this aggressive treatment strategy is high; however, overall mortality can be low in specialized centers." "The aim of this study was to assess the safety of gastric resections with anastomosis during CRS and HIPEC. Between 2005 and 2008, 204 patients underwent CRS and HIPEC at our tertiary referral centre. Of these, 37 procedures (male/female 24/13, median age 55 years) included gastric resections. The clinical data of all patients were introduced into a database and analyzed with respect to the morbidity associated with the gastric resections. Of all patients included, 16 had pseudomyxoma peritonei, 11 gastric carcinoma, 4 ovarian carcinoma, 3 malignant peritoneal mesothelioma, and 3 colon carcinoma. Twenty-seven patients had previous surgery (n=22) and/or systemic chemotherapy (n=18). Fifteen total gastrectomies, 3 subtotal gastrectomies, 12 distal gastrectomies, and 7 gastric wedge resections were performed during CRS. The overall postoperative morbidity was 45%; main surgical complications were pancreatitis (n=6), abdominal abscess (n=4), bile leakage (n=2), and digestive fistula (leakage of ileorectostomy and small bowel perforation) (n=2). However, no complications occurred at the site of the esophageal anastomosis (n=15), gastric anastomosis (n=15) or gastric suture (n=7). No patient died postoperatively during the hospitalization period. CRS in combination with HIPEC is associated with high postoperative morbidity; however, anastomosis following total or subtotal gastrectomy is safe in experienced centers," wrote P. Piso and colleagues, University Medical Center, Department of Surgery. The researchers concluded: "No leakages related to gastric resections occurred in this high-risk patient group." Piso and colleagues published the results of their research in Annals of Surgical Oncology (Safety of gastric resections during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis. Annals of Surgical Oncology, 2009;16(8):2188-94). For additional information, contact P. Piso, University Medical Center Regensburg, Dept. of Surgery, Regensburg, Germany. The publisher of the journal Annals of Surgical Oncology can be contacted at: Springer, 233 Spring Street, New York, NY 10013, USA. Keywords: Germany, Regensburg, Carcinoma Therapy, Chemotherapy, Drug Therapy, Gastric Cancer, Gastroenterology, Gastrointestinal, Gynecology, Mesothelioma, Oncology, Ovarian Cancer, Ovarian Carcinoma, Pseudomyxoma Peritonei, Surgery, Surgical Oncology, Treatment, Women's Health. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.
|
